NCT00150371已完成3 期
A Multicenter, 12 Week Treatment Single Step Titration Open-Label Study Assessing The % Of Patients Achieving Ldl-C Target With Atorvastatin Starting Doses Of 10mg, 20mg, 40mg and 80mg.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.85 个研究点 分布在 1 个国家目标入组 1,100 人开始时间: 2004年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,100
- 试验地点
- 85
- 主要终点
- Proportion (%) of subjects achieving their LDL-C target after 12 weeks of treatment according to their 10-year CHD risk category (based on the new canadian guidelines on the management and treatment of dyslipidemia).
研究概览
简要总结
The objective of this study is to assess the effectiveness of an atorvastatin treatment regimen involving starting doses between 10 and 80 mg, followed by a single-step titration (except for subjects started at 80mg), if required
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 30 to 79 years old
- •Triglyceride level 6.8 mmol/L at screening
- •LDL-C of 5.7 mmol/L at screening
排除标准
- •Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception. The latter are defined as: abstinence, surgical sterilization, oral contraceptives for at least 3 cycles, intrauterine device, implant, depot injection, or barrier method in conjunction with contraceptive foam or jelly.
- •Subjects whose blood cholesterol levels are controlled (LDL-C targets) with statins other than atorvastatin
- •Subjects receiving statin doses higher than the following: 10-40mg for simvastatin , 20-40mg for fluvastatin, pravastatin and lovastatin and 10-20 mg for rosuvastatin. Subjects already treated with atorvastatin at the time of screening are not eligible unless atorvastatin has been discontinued at least 2 months prior to screening
- •Subjects receiving 2 or more lipid lowering agents are excluded (statins + resins or fibrates or niacin or fish oils)
结局指标
主要结局
Proportion (%) of subjects achieving their LDL-C target after 12 weeks of treatment according to their 10-year CHD risk category (based on the new canadian guidelines on the management and treatment of dyslipidemia).
次要结局
- The global proportion (%) of patients reaching targets when risk categories are combined The proportion (%) of subjects achieving BOTH their LDL-C and TC/HDL-C ratio targets after 6 and 12 weeks of treatment, globally and according to their 10-year
研究者
研究点 (85)
Loading locations...
相似试验
已完成
4 期
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High CholesterolDyslipidemiasNCT00644670Pfizer's Upjohn has merged with Mylan to form Viatris Inc.232
已完成
4 期
Atorvastatin Study For The Treatment Of High Cholesterol In Patients From ThailandDyslipidemiasNCT00647543Pfizer's Upjohn has merged with Mylan to form Viatris Inc.242
已完成
4 期
A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High CholesterolHyperlipidemiasNCT00645424Pfizer's Upjohn has merged with Mylan to form Viatris Inc.155
已完成
4 期
Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMIMyocardial InfarctionNCT02590653Penza State University200
已完成
2 期
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)Type 1 DiabetesNCT00529191Children's Hospital of Philadelphia40